These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32614981)

  • 21. APOE genotype dependent molecular abnormalities in the cerebrovasculature of Alzheimer's disease and age-matched non-demented brains.
    Ojo JO; Reed JM; Crynen G; Vallabhaneni P; Evans J; Shackleton B; Eisenbaum M; Ringland C; Edsell A; Mullan M; Crawford F; Bachmeier C
    Mol Brain; 2021 Jul; 14(1):110. PubMed ID: 34238312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining.
    Hadar A; Milanesi E; Squassina A; Niola P; Chillotti C; Pasmanik-Chor M; Yaron O; Martásek P; Rehavi M; Weissglas-Volkov D; Shomron N; Gozes I; Gurwitz D
    Transl Psychiatry; 2016 Oct; 6(10):e909. PubMed ID: 27701409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease.
    Mendonça CF; Kuras M; Nogueira FCS; Plá I; Hortobágyi T; Csiba L; Palkovits M; Renner É; Döme P; Marko-Varga G; Domont GB; Rezeli M
    Neurobiol Dis; 2019 Oct; 130():104509. PubMed ID: 31207390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced GAP-43 message levels are associated with increased neurofibrillary tangle density in the frontal association cortex (area 9) in Alzheimer's disease.
    Coleman PD; Kazee AM; Lapham L; Eskin T; Rogers K
    Neurobiol Aging; 1992; 13(6):631-9. PubMed ID: 1283445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease.
    Sathe G; Na CH; Renuse S; Madugundu AK; Albert M; Moghekar A; Pandey A
    Proteomics Clin Appl; 2019 Jul; 13(4):e1800105. PubMed ID: 30578620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease.
    Chou JL; Shenoy DV; Thomas N; Choudhary PK; Laferla FM; Goodman SR; Breen GA
    J Proteomics; 2011 Apr; 74(4):466-79. PubMed ID: 21237293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of DISC1 on Alzheimer's disease cell models assessed by iTRAQ proteomics analysis.
    Lu J; Huang R; Peng Y; Wang H; Feng Z; Fan Y; Zeng Z; Wang Y; Wei J; Wang Z
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34981809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A frontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex.
    Talbot K; Young RA; Jolly-Tornetta C; Lee VM; Trojanowski JQ; Wolf BA
    Neurochem Int; 2000 Jul; 37(1):17-31. PubMed ID: 10781842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: identification of common and distinct olfactory targets across Alzheimer-related co-pathologies.
    Zelaya MV; Pérez-Valderrama E; de Morentin XM; Tuñon T; Ferrer I; Luquin MR; Fernandez-Irigoyen J; Santamaría E
    Oncotarget; 2015 Nov; 6(37):39437-56. PubMed ID: 26517091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery.
    Bai B; Vanderwall D; Li Y; Wang X; Poudel S; Wang H; Dey KK; Chen PC; Yang K; Peng J
    Mol Neurodegener; 2021 Aug; 16(1):55. PubMed ID: 34384464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression.
    Hales CM; Dammer EB; Deng Q; Duong DM; Gearing M; Troncoso JC; Thambisetty M; Lah JJ; Shulman JM; Levey AI; Seyfried NT
    Proteomics; 2016 Dec; 16(23):3042-3053. PubMed ID: 27718298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease.
    Zhou M; Haque RU; Dammer EB; Duong DM; Ping L; Johnson ECB; Lah JJ; Levey AI; Seyfried NT
    Clin Proteomics; 2020; 17():19. PubMed ID: 32514259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 27-Plex Tandem Mass Tag Mass Spectrometry for Profiling Brain Proteome in Alzheimer's Disease.
    Wang Z; Yu K; Tan H; Wu Z; Cho JH; Han X; Sun H; Beach TG; Peng J
    Anal Chem; 2020 May; 92(10):7162-7170. PubMed ID: 32343560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models.
    Martiskainen H; Viswanathan J; Nykänen NP; Kurki M; Helisalmi S; Natunen T; Sarajärvi T; Kurkinen KM; Pursiheimo JP; Rauramaa T; Alafuzoff I; Jääskeläinen JE; Leinonen V; Soininen H; Haapasalo A; Huttunen HJ; Hiltunen M
    Neurobiol Aging; 2015 Feb; 36(2):1221.e15-28. PubMed ID: 25281018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative proteomics reveals that PEA15 regulates astroglial Aβ phagocytosis in an Alzheimer's disease mouse model.
    Lv J; Ma S; Zhang X; Zheng L; Ma Y; Zhao X; Lai W; Shen H; Wang Q; Ji J
    J Proteomics; 2014 Oct; 110():45-58. PubMed ID: 25108202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer disease pathology and the cerebrospinal fluid proteome.
    Dayon L; Núñez Galindo A; Wojcik J; Cominetti O; Corthésy J; Oikonomidi A; Henry H; Kussmann M; Migliavacca E; Severin I; Bowman GL; Popp J
    Alzheimers Res Ther; 2018 Jul; 10(1):66. PubMed ID: 30021611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study.
    Russell CL; Heslegrave A; Mitra V; Zetterberg H; Pocock JM; Ward MA; Pike I
    Rapid Commun Mass Spectrom; 2017 Jan; 31(2):153-159. PubMed ID: 27813239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
    Grothe MJ; Sepulcre J; Gonzalez-Escamilla G; Jelistratova I; Schöll M; Hansson O; Teipel SJ;
    Brain; 2018 Sep; 141(9):2755-2771. PubMed ID: 30016411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of polypeptides in neurofibrillary tangles and total homogenates of brains with Alzheimer's disease by tandem mass spectrometry.
    Minjarez B; Valero Rustarazo ML; Sanchez del Pino MM; González-Robles A; Sosa-Melgarejo JA; Luna-Muñoz J; Mena R; Luna-Arias JP
    J Alzheimers Dis; 2013; 34(1):239-62. PubMed ID: 23229080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimer's disease.
    Toomey CE; Heywood W; Benson BC; Packham G; Mills K; Lashley T
    Brain Pathol; 2020 Jul; 30(4):794-810. PubMed ID: 32267026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.